Overview

A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma

Status:
Completed
Trial end date:
2021-02-09
Target enrollment:
Participant gender:
Summary
The purpose of the study was to evaluate the efficacy of enzalutamide in participants with advanced hepatocellular carcinoma (HCC) as measured by overall survival (OS). This study also evaluated the safety of enzalutamide; pharmacokinetics of enzalutamide and the active metabolite N-desmethyl and Progression Free Survival (PFS) of enzalutamide as compared to placebo in participants with advanced HCC.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc.
Collaborators:
Medivation, Inc.
Pfizer